Vector Science & Therapeutics and Caresyntax Announce Real-World Evidence Partnership for VectorMist
Caresyntax will design and operate a multi-phase real-world evidence program for Vector, culminating in a prospective comparative registry across a network of partner surgical facilities. The program ...
Vector Science & Therapeutics, Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced the expansion of its intellectual property portfolio to 15 patent applications developed and filed over ...
Vector Science and Therapeutics Corp. (TSXV: PAIN), a pharmaceutical-grade peptide and precision drug delivery company, today ...
Vector Science & Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced an exclusive licensing and manufacturing agreement with LyoGenesis Plus ("LyoGenesis"), a cGMP ...
Former Wisconsin Governor and U.S. Secretary of Health and Human Services Brings Extensive Healthcare Leadership to Pioneer of Transdermal Drug Delivery Technology MEQUON, Wis., April 30, 2026 ...
MEQUON, Wis., June 8, 2026 /PRNewswire/ -- Vector Science & Therapeutics Corp. (TSXV: PAIN) today announced the appointment of Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board ...
Vancouver, British Columbia--(Newsfile Corp. - April 24, 2026) - Vector Science and Therapeutics Corp. (TSXV: PAIN) (formerly OpenSesame Acquisition Corp.) ("Vector" or the "Company") is pleased to ...
Option agreement Supports Vector's Entry into the $80.8 Billion Peptide Market with 22 Novel Pharmaceutical-Grade Formulations FDA-Registered, cGMP Manufacturing-- MPP operates a modern 35,000 sq. ft.
1mon
Vector Science & Therapeutics Names Dexter Fowler as Chief Athletic Officer for Its Valor Platform
Year MLB Veteran and 2016 World Series Champion Joins Valor, Vector's Athlete Platform, to Make Sure the Next Generation Plays Longer and Hurts Less MEQUON, Wis., June 12, 2026 /PRNewswire/ -- Vector ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results